**SUPPLEMENTAL MATERIAL**

Appendix 1. Patients meeting institution-specific tocilizumab criteria

|  |  |  |
| --- | --- | --- |
| All of the following must be met: | n (%) | Number of patients with available data |
| Confirmed or highly suspected COVID-19 | 60 (100.0) | 60 |
| Requiring minimum of 4 liters nasal cannula  | 56a (93.3) | 60 |
| Clinical deterioration based on physician discretion  | 60 (100.0) | 60 |
| At least 2 of the following: Interleukin-6 >40 pg/mL C-reactive protein >10 mg/dL Lactate dehydrogenase >350 U/L Ferritin >1000 ng/mL D-dimer >1 mcg/mL | 33 (75.0)50 (83.3)52 (92.9)36 (64.3)37 (64.9) | 4460565657 |

aFour patients received tocilizumab but did not meet criteria: room air (1), 2 liters nasal cannula (3)

Appendix 2. Clinical measures within 14 days of receiving tocilizumab

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| n (%) | All patients (N=60) | Died (n=9) | Alive (n=51) | Discharged (n=22) | Still Hospitalized (n=29) | ICU(n=52) | Floor(n=8) | Invasive mechanical ventilation (n=29) | No invasive mechanical ventilation (n=31) |
| Renal complications Acute kidney injurya Renal replacement therapyb | 33 (55.0)12 (20.0) | 9 (100.0)3 (33.3) | 24 (47.1)9 (17.6) | 4 (18.2)0 (0.0) | 20 (69.0)9 (31.0) | 31 (59.6)12 (23.1) | 2 (25.0)0 (0.0) | 24 (82.8)12 (41.4) | 9 (29.0)0 (0.0) |
| Liver complications Transaminitisc Bilirubinemiad | 14 (23.3)10 (16.7) | 4 (44.4)4 (44.4) | 10 (19.6)6 (11.8) | 4 (18.2)2 (9.1) | 6 (20.7)4 (13.8) | 10 (19.2)8 (15.4) | 4 (50.0)2 (25.0) | 7 (24.1)6 (20.7) | 7 (22.6)4 (12.9) |
| Cardiovascular complications Vasopressor use | 24 (40.0) | 5 (55.6) | 19 (37.3) | 1 (4.5) | 18 (62.1) | 24 (46.2) | 0 (0.0) | 23 (79.3) | 1 (3.2) |
| Respiratory complications ARDS, n (%)e Mild (201<PaO2/FiO2≤300) Moderate (101<PaO2/FiO2≤200) Severe (0<PaO2/FiO2 ≤100) Proning ECMO Paralytics Inhaled nitric oxide | 4 (6.7)20 (33.3)33 (55.0)24 (40.0)3 (5.0)19 (31.7)5 (8.3) | 0 (0.0)2 (22.2)7 (77.8)6 (66.7)0 (0.0)4 (44.4)1 (11.1) | 4 (7.8)18 (35.3)26 (51.0)18 (35.3)3 (5.9)15 (29.4)4 (7.8) | 4 (18.2)9 (40.9)6 (27.3)4 (18.2)0 (0.0)0 (0.0)0 (0.0) | 0 (0.0)9 (31.0)20 (69.0)14 (48.3)3 (10.3)15 (51.7)4 (13.8) | 2 (3.8)18 (34.6)31 (59.6)23 (44.2)3 (5.8)19 (36.5)5 (9.6) | 2 (25.0)2 (25.0)2 (25.0)1 (12.5)0 (0.0)0 (0.0)0 (0.0) | 0 (0.0)12 (41.4)17 (58.6)16 (55.2)3 (10.3)19 (65.5)4 (13.8) | 4 (12.9)8 (25.8)16 (51.6)8 (25.8)0 (0.0)0 (0.0)1 (3.2) |
| Mode of oxygen supplementationf Nasal cannula  Venti-mask Nonrebreather High-flow nasal cannula BiPAP Invasive mechanical ventilation | 12 (20.0)0 (0.0)3 (5.0)14 (23.3)2 (3.3)29 (48.3) | 0 (0.0)--1 (11.1)2 (22.2)0 (0.0)6 (66.7) | 12 (23.5)--2 (3.9)12 (23.5)2 (3.9)23 (45.1) | 12/22--1/227/221 (4.5)1 (4.5) | 0 (0.0)--1 (3.4)5 (17.2)1 (3.4)22 (75.9) | 6 (11.5)--2 (3.8)13 (25.0)2 (3.8)29 (55.8) | 6 (75.0)--1 (12.5)1 (12.5)0 (0.0)0 (0.0) | ------------ | ------------ |
| SOFA score, median (range)g | 4 (0-14) | 6 (4-11) | 3 (0-14) | 2 (0-4) | 6 (1-14) | 4.5 (0-14) | 2 (1-4) | 8 (2-14) | 2.5 (0-10) |

aSerum creatinine increase ≥0.3 mg/dL within 48 hours or increase by 50% from baseline

b3 hemodialysis, 9 continuous veno-venous hemofiltration (CVVH)

cALT/AST > 5x ULN

dTotal bilirubin >1.3 mg/dL

eCategorized by lowest PaO2/FiO2 ratio

fCategorized by highest degree of oxygen support

gCategorized by highest SOFA score

Appendix 3. Infectious complications within 30 days of receiving tocilizumab (N=60)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Source | Pathogen identified | Time after administration (days) | Concomitant immunosuppressants |
| Patient 1  | Blood  | MRSA | 28 | Corticosteroids |
| Patient 2  | Tracheal Aspirate | MRSA | 9 | Corticosteroids |
| Tracheal Aspirate | MSSA | 28 |
| Blood | *Klebsiella pneumoniae* | 30 |
| Patient 3  | Blood | Diptheroids | 11 | Corticosteroids |
| Blood | Diptheroids, *Enterococcus faecalis* | 13 |
| Blood | *Enterococcus faecalis* | 24 |
| Patient 4  | Blood | *Serratia marcescens* | 15 | Corticosteroids |
| Tracheal Aspirate | *Serratia marcescens* | 15 |
| Patient 5  | Tracheal Aspirate | MSSA | 5 | None |
| Patient 6  | Bronchial aspirate | *Pseudomonas aeruginosa* | 13 | Corticosteroids |
| Blood | *Staphylococcus capitis* | 21 |
| Tracheal Aspirate | *Pseudomonas aeruginosa, Stenotrophomonas maltophilia*  | 23 |
| Patient 7  | Tracheal Aspirate | MRSA, *Pseudomonas aeruginosa* | 24 | Corticosteroids |
| Patient 8  | Blood | *Enterococcus faecalis* | 2 | Corticosteroids |
| Blood | *Candida glabrata* | 4 |
| Patient 9  | Tracheal Aspirate | *Escherichia coli* | 8 | Corticosteroids |
| Tracheal Aspirate | *Klebsiella pneumoniae* | 15 |
| Tracheal Aspirate | MSSA | 22 |
| Patient 10 | Blood  | *Staphylococcus epidermidis* | 24 | None |
| Patient 11 | Urine | *Escherichia coli* | 18 | None |
| Blood  | *Staphylococcus epidermidis* | 22 |
| Patient 12 | Endotracheal  | *Klebsiella aerogenes* | 2 | None |
| Tracheal Aspirate | *Klebsiella aerogenes* | 24 |
| Patient 13  | Sputum Induced | *Klebsiella aerogenes* | 6 | None |
| Patient 14  | Blood  | *Staphylococcus epidermidis* | 17 | Corticosteroids |
| Patient 15  | Blood | *Staphylococcus hominis* | 9 | None |
| Patient 16  | Blood  | *Staphylococcus epidermidis* | 10 | Corticosteroids |
| Sputum Expectorated | *Klebsiella aerogenes* | 10 |

MRSA methicillin-resistant *Staphylococcus aureus*; MSSA methicillin-sensitive *Staphylococcus aureus*